Milea Timbergen

210 Supplementary Table 5. (continued) Kim et al. 43 (2016), Oncology Letters Salas et al. 49 (2010), Genes, Chromosomes & Cancer Nishida et al. 42 (2016), Oncology Letters Mullen et al. 20 (2013), The Oncologist Mussi et al. 41 (2016), Tumori Broekhoven et al. 22 (2015), Annals of Surgical Oncology Colombo et al. 23 (2013), Cancer CTNNB1 genotyping • FFPE • 2-step PCR using nested primers • PCR amplification of exon 3 • Direct sequencing of amplified PCR product • FT • PCR amplification of exon 3 • Direct sequencing of amplified PCR product • Lymphocytes as non-mutated controls • FFPE/FT • PCR amplification of exon 3 • Direct sequencing of amplified PCR product • FFPE • SNaPshot assay • PCR amplification of exon 3 • Direct sequencing of amplified PCR product • FFPE • PCR amplification of exon 3 • Direct sequencing of amplified PCR product • FFPE • PCR amplification of exon 3 • Direct sequencing of amplified PCR product • FFPE • PCR amplification of exon 3 • Direct sequencing of amplified PCR product Tumour size in centimetres, median (range) NS 7 (1-30) 8.7 (4.5-18) 7.0 (0.8-29) 4.6 (1-11) NS 7 (1-32) Tumour size 0-50 mm NS NS 4 (31%) NS NS 61 (61%) NS 51-100 mm NS NS 3 (23%) NS NS 32 (32%) NS > 100 mm NS NS 6 (46%) NS NS 8 (8%) NS <50 mm NS NS NS 29 (25%) NS NS NS ≥ 50 mm NS NS NS 86 (75%) NS NS NS < 60 mm 96 (61%) NS NS NS NS NS NS > 60 mm 61 (39%) NS NS NS NS NS NS Depth Superficial 45 (28%) NS NS NS NS 21 (21%) NS Deep 114 (72%) NS NS NS NS 80 (80%) NS Gardner’s syndrome 0 10 (5%) NS NS NS 0 0 7